FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- Cedar Point attraction mishap injures 2 riders
- U.S. coal exports undermine clean air efforts, experts say
- U.S. coal exports undermine energy efforts, experts say
- Tentative deal reached on VA reforms
- Cellphone users can soon declare freedom from wireless carriers
- Lawmakers say answering Census survey should be voluntary
- Cornyn, Cuellar tout border bill amid uncertainty
- Automatically renewing Obamacare plans may backfire
- Lightning strikes 14 in Calif., leaves 2 critically hurt
- Trial to begin for video in Oklahoma City bombing
- Tyrannosaurs ran in packs, fossils prove